Aim Immunotech Inc.

AIM ImmunoTech Provides Routine Update on Annual Filings

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

AIM ImmunoTech Announces Closing of its Rights Offering

AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million